Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Netherlands Cancer Institute
Dana-Farber Cancer Institute
Tempus AI
North Eastern German Society of Gynaecological Oncology
Consorzio Oncotech